Motus gi holdings, inc. announces expedite study initiated by boston medical center to evaluate clinical effectiveness of pure-vu® system for improving bowel preparation rates

Motus gi holdings, inc. announced that the boston medical center (bmc) has initiated the expedite clinical study to evaluate the effectiveness of the pure-vu system on bowel preparation rates. the expedite study will enroll up to 50 inpatients and 50 outpatients over a 12-month study period. the study will evaluate bowel preparation adequacy in the 100 patients undergoing a colonoscopy with the pure-vu system against inpatient and outpatient populations that had a colonoscopy over the prior 24 months preceding availability of the pure-vu system. the rate of bowel preparation adequacy will be measured before and after pure-vu system using the boston bowel preparation scale (bbps), a validated assessment instrument that is used broadly by gastroenterologists on a scale of 0 to 3 per segment, requiring a minimum score of 2 to be considered adequately prepped. the bbps scale has been used in all pure-vu system clinical studies performed to date including the reduce inpatient colonoscopy study for which results were presented at digestive disease week in may 2019. findings from the reduce study, showed per segment bbps improved from an average baseline of 1.74, 1.74 and 1.5 to 2.89, 2.91 and 2.86, respectively, with a statistically significant p value of .001 for all three segments of the colon after pure-vu system use.
MOTS Ratings Summary
MOTS Quant Ranking